Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AB122 + TAS-120 + nab-paclitaxel + gemcitabine
- Development stage
- Phase 1
- Lead developer
- Arcus Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This drug regimen is a combination therapy composed of four agents: **AB122** (a fully human monoclonal antibody that acts as an anti-PD-1 immune checkpoint inhibitor developed by Arcus Biosciences), **TAS-120** (futibatinib, an irreversible FGFR inhibitor used in targeted cancer therapy), **nab-paclitaxel** (nanoparticle albumin-bound paclitaxel, a microtubule inhibitor chemotherapy formulated for improved delivery), and **gemcitabine** (a nucleoside analog chemotherapy agent with antimetabolite activity). The combination is used in investigational settings, primarily for advanced or metastatic solid tumors, including pancreatic and potentially other cancers. The regimen aims to combine immunotherapy, targeted therapy, and cytotoxic chemotherapy for synergistic antitumor response.
- Other names
- futibatinibnab-paclitaxelgemcitabinepaclitaxel albumin-bound
02
Targets
DNAFGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDCD1 (Programmed cell death protein 1 receptor)RNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on AB122 + TAS-120 + nab-paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AB122 + TAS-120 + nab-paclitaxel + gemcitabine.